Theravance Biopharma Inc (TBPH) Stock Ticker
TBPH right now
Market factors today
Unlock the full TBPH picture
About Theravance Biopharma Inc
Theravance Biopharma, Inc., a biopharmaceutical company, develops and commercializes medicines in the United States. It offers YUPELRI, an once-daily, nebulized long-acting muscarinic antagonist for the treatment of chronic obstructive pulmonary disease (COPD); and Ampreloxetine an investigational, once-daily norepinephrine reuptake inhibitor, Which is in Phase 3 clinical trials for symptomatic neurogenic orthostatic hypotension (nOH) in patients with Multiple System Atrophy (MSA). It has a strategic collaboration agreement with Viatris Inc. for the development and commercialization of revefenacin, including YUPELRI inhalation solution. Theravance Biopharma, Inc. was incorporated in 2013 and is based in South San Francisco, California.
TBPH stock facts
| Ticker symbol | TBPH |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market cap | $882.6M |
| CEO | Rick E. Winningham |
| Employees | 90 |
| Headquarters | South San Francisco, CA, US |
| IPO date | 2014-05-16 |
| Website | www.theravance.com |
What you can see for TBPH on Tickr
Live TBPH price chart with overlays, the options chain, implied move, IV rank, options flow and Strategy Lab, financial statements and consensus estimates, analyst ratings, catalysts, news with AI scoring, and an AI chat that has read the TBPH report.
Rankings
FAQ
What is the ticker symbol for Theravance Biopharma Inc?
The ticker symbol for Theravance Biopharma Inc is TBPH, listed on the NASDAQ.
What is TBPH?
Theravance Biopharma, Inc., a biopharmaceutical company, develops and commercializes medicines in the United States. It offers YUPELRI, an once-daily, nebulized long-acting muscarinic antagonist for the treatment of chronic obstructive pulmonary disease (COPD); and Ampreloxetine an investigational, once-daily norepinephrine reuptake inhibitor, Which is in Phase 3 clinical trials for symptomatic…